• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by PaxMedica, Inc.

    9/9/22 4:24:24 PM ET
    $PXMD
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $PXMD alert in real time by email
    SC 13G 1 tm2225532d2_sc13g.htm SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934
    (Amendment No. )*

     

    PAXMEDICA, INC.

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    70424C104

    (CUSIP Number)

     

    August 25, 2022

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)
    x Rule 13d-1(c)
    ¨ Rule 13d-1(d)

     

    *                 The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

      1. Name of Reporting Persons:
    Blue Cane Partners, LLC
      2. Check the Appropriate Box if a Member of a Group
        (a) ¨
        (b) ¨
      3. SEC Use Only
      4. Citizenship or Place of Organization:
    [Delaware]
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5. Sole Voting Power:
    1,175,000 (1)
    6. Shared Voting Power:
    0
    7. Sole Dispositive Power:
    1,175,000 (1)
    8. Shared Dispositive Power:
    0
      9. Aggregate Amount Beneficially Owned by Each Reporting Person:
    1,175,000 (1)
      10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨
      11. Percent of Class Represented by Amount in Row (9):
    9.9% (1)(2)
      12. Type of Reporting Person (See Instructions):
    OO
               

     

    (1)Excludes 156,057 shares of common stock, par value $0.0001 per share (the “Common Stock”), as a result of beneficial ownership limitation provisions contained in certain of the Issuer’s security instruments owned by Blue Cane Partners, LLC.
    (2)Percentage calculated based upon 11,779,475 shares of Common Stock outstanding as of September 9, 2022, based on information obtained from the Issuer.

     

     

     

     

      1. Name of Reporting Persons:
    Craig Kesselman
      2. Check the Appropriate Box if a Member of a Group
        (a) o
        (b) o
      3. SEC Use Only
      4. Citizenship or Place of Organization:
    United States Citizen
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5. Sole Voting Power:
    1,175,000 (1)
    6. Shared Voting Power:
    0
    7. Sole Dispositive Power:
    1,175,000 (1)
    8. Shared Dispositive Power:
    0
      9. Aggregate Amount Beneficially Owned by Each Reporting Person:
    1,175,000 (1)
      10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨
      11. Percent of Class Represented by Amount in Row (9):
    9.9% (1)(2)
      12. Type of Reporting Person (See Instructions):
    IN
               

     

    (3)Excludes 156,057 shares of Common Stock as a result of beneficial ownership limitation provisions contained in certain of the Issuer’s security instruments owned by Blue Cane Partners, LLC.
    (4)Percentage calculated based upon 11,779,475 shares of Common Stock outstanding as of September 9, 2022, based on information obtained from the Issuer.

     

     

     

     

    Item 1. (a). Name of Issuer:
    PaxMedica, Inc.
      (b).

    Address of Issuer’s Principal Executive Offices:
    303 South Broadway, Suite 125

    Tarrytown, NY 10591

    Item 2(a).

    Name of Person Filing:

    Blue Cane Partners, LLC

    Craig Kesselman

    Item 2(b).

    Address of Principal Business Office:

    3411 Silverside Road Tatnal Building #104

    Wilmington, DE 19810

    Item 2(c).

    Citizenship:

    Blue Cane Partners, LLC - [Delaware]

    Craig Kesselman - United States

    Item 2(d). Title of Class of Securities:
    Common Stock, par value $0.0001
    Item 2(e). CUSIP Number:
    70424C104
     
    Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:
      Not Applicable.
    Item 4. Ownership.
      (a)

    Amount beneficially owned:(1)

    Blue Cane Partners, LLC - 1,175,000 

    Craig Kesselman - 1,175,000 

      (b)

    Percent of class:

    Blue Cane Partners, LLC – 9.9%  (1)(2)

    Craig Kesselman – 9.9%  (1)(2)

      (c) Number of shares as to which such person has:
        (i)

    Sole power to vote or to direct the vote:

    Blue Cane Partners, LLC - 1,175,000 

    Craig Kesselman - 1,175,000 

        (ii)

    Shared power to vote or to direct the vote:

    Blue Cane Partners, LLC - 0 

    Craig Kesselman - 0

        (iii)

    Sole power to dispose or to direct the disposition of:

    Blue Cane Partners, LLC - 1,175,000 

    Craig Kesselman - 1,175,000

        (iv)

    Shared power to dispose or to direct the disposition of:

    Blue Cane Partners, LLC - 0 

    Craig Kesselman - 0

     

     

     

     

    Item 5. Ownership of Five Percent or Less of a Class
      Not Applicable.
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
      Not Applicable.
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.
      Not Applicable.
    Item 8. Identification and Classification of Members of the Group.
      Not Applicable.
    Item 9. Notice of Dissolution of Group.
      Not Applicable.
    Item 10. Certification.
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.
     

    (1)    Shares reported herein for Blue Cane Partners, LLC (“Blue Cane”) are held directly by Blue Cane. Craig Kesselman (“Mr. Kesselman” and, together with Blue Cane, the “Reporting Persons”), as a member of Blue Cane, has voting and dispositive control over the securities held by Blue Cane and may be deemed to be a beneficial owner of such securities. The amounts beneficially owned by the Reporting Persons exclude 156,057 shares of Common Stock as a result of beneficial ownership limitation provisions contained in certain of the Issuer’s security instruments owned by Blue Cane. Mr. Kesselman disclaims beneficial ownership of the securities held by Blue Cane, and this report shall not be deemed an admission that he is the beneficial owner of such shares for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, or for any other purpose, except to the extent of his pecuniary interest therein.

     

    (2)     Percentage calculated based upon 11,779,475 shares of Common Stock outstanding as of September 9, 2022, based on information obtained from the Issuer.

    Exhibits Exhibit
    99.1 Joint Filing Agreement between the Reporting Persons.

     

     

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated:  September 9, 2022

     

      BLUE CANE PARTNERS, LLC
         
      By: /s/ Craig Kesselman
      Name: Craig Kesselman
      Title: Member
         
         
        /s/ Craig Kesselman
        Craig Kesselman

     

     

     

    Get the next $PXMD alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $PXMD

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PXMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PaxMedica Announces First Patent Allowance for Suramin Intranasal Formulation in the treatment of Autism Spectrum Disorder and Other Conditions

      BOSTON, MA / ACCESSWIRE / January 14, 2025 / PaxMedica, Inc. (OTC:PXMD), a clinical-stage biopharmaceutical company dedicated to advancing treatments for neurological disorders, is pleased to announce it has received a Notification to Grant Patent Right for Chinese Invention Patent Application No: 2020800553323, Compositions and methods for treating cognitive, social, or behavioral disabilities and neurodevelopmental disorders, such as those found in individuals impacted by autism.Howard Weisman, CEO of PaxMedica commented, "This is an extraordinary milestone for PaxMedica, as this is the first jurisdiction in the world where intellectual property protection of any form of suramin has been a

      1/14/25 8:00:00 AM ET
      $PXMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • PaxMedica Secures Immediate Exercise of Warrants

      TARRYTOWN, NY / ACCESSWIRE / September 3, 2024 / PaxMedica, Inc. (OTC:PXMD), a clinical-stage biopharmaceutical company dedicated to advancing treatments for neurological disorders, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 4,423,080 shares of common stock of the originally issued in November 2023, having an exercise price of 1.30 per share, at a reduced exercise price of $0.20 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (No. 333-275416). The offering is expected to close on or about

      9/3/24 8:00:00 AM ET
      $PXMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness Infection

      Company provides update on regulatory progress towards US NDA submission TARRYTOWN, NY / ACCESSWIRE / August 27, 2024 / PaxMedica, Inc. (OTC:PINKPXMD), a clinical-stage biopharmaceutical company dedicated to advancing treatments for neurological disorders, is pleased to announce a significant milestone in its global health efforts. The Malawi Ministry of Health has informed the company that a patient suffering from the potentially fatal parasitic infection known as Human Africa Trypanosomiasis Brucei Rhodesiense, (HAT), commonly referred to as African Sleeping Sickness, has recently received treatment with PAX-101, an intravenous form of Suramin, and is recovering at home. The Rhodesiense st

      8/27/24 8:00:00 AM ET
      $PXMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $PXMD
    SEC Filings

    See more
    • PaxMedica Inc. filed SEC Form 8-K: Leadership Update

      8-K - PaxMedica, Inc. (0001811623) (Filer)

      2/6/25 4:05:19 PM ET
      $PXMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form NT 10-Q filed by PaxMedica Inc.

      NT 10-Q - PaxMedica, Inc. (0001811623) (Filer)

      11/14/24 4:05:10 PM ET
      $PXMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form EFFECT filed by PaxMedica Inc.

      EFFECT - PaxMedica, Inc. (0001811623) (Filer)

      10/16/24 12:15:11 AM ET
      $PXMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $PXMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Weisman Howard J. covered exercise/tax liability with 2,927 shares, decreasing direct ownership by 8% to 34,748 units (SEC Form 4)

      4 - PaxMedica, Inc. (0001811623) (Issuer)

      3/14/24 4:50:14 PM ET
      $PXMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Sheldon Stephen covered exercise/tax liability with 3,356 shares, decreasing direct ownership by 25% to 10,137 units (SEC Form 4)

      4 - PaxMedica, Inc. (0001811623) (Issuer)

      3/14/24 4:49:38 PM ET
      $PXMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Rome Zachary covered exercise/tax liability with 4,904 shares, decreasing direct ownership by 32% to 10,244 units (SEC Form 4)

      4 - PaxMedica, Inc. (0001811623) (Issuer)

      3/14/24 4:48:37 PM ET
      $PXMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $PXMD
    Leadership Updates

    Live Leadership Updates

    See more
    • PaxMedica Appoints David Hough M.D. as Chief Medical Officer

      Announces Additional Management Changes; Independent Directors Now Majority of Board TARRYTOWN, NY, Aug. 16, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (NASDAQ:PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (APT) for the treatment of Autism Spectrum Disorder (ASD) and other serious conditions with intractable neurologic symptoms, today announced the return of David Hough, M.D., as Chief Medical Officer (CMO) of PaxMedica, effective immediately.  Dr. Hough  has been a key consultant to the company during 2023 and was the company's CMO from 2020-2022. He is board-certified in both adult and geriatric psy

      8/16/23 8:30:00 AM ET
      $PXMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • PaxMedica, Inc. Provides Business Update and Reports Third Quarter 2022 Financial Results

      -PXMD Strengthened Executive Team and Board of Directors With Recent Appointments After IPO in August 2022- -Phase 3 Results for HAT-301 Trial Expected in First Half 2023- TARRYTOWN, NY, Nov. 15, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (NASDAQ:PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies ("APT") for the treatment of disorders with intractable neurologic symptoms, today provided a business update and reported financial results for the third quarter of 2022, ended September 30, 2022. Howard Weisman, Chief Executive Officer of PaxMedica, commented, "The third quarter was PaxMedica's first as a publ

      11/15/22 8:00:00 AM ET
      $PXMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • PaxMedica Appoints Stefan Schwabe MD, PhD as Chief Medical Officer

      Dr. Schwabe brings 30+ years of Clinical Experience in the Pharmaceutical Industry  TARRYTOWN, NY, Oct. 24, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (NASDAQ:PXMD), a clinical-stage biopharmaceutical company focused on the development of anti-purinergic drug therapies ("APT") for the treatment of disorders with intractable neurologic symptoms such as autism spectrum disorder ("ASD"), today announced the appointment of Dr. Stefan Schwabe MD, PhD as Chief Medical Officer.  In this role, Dr. Schwabe will be responsible for overseeing and directing product development activities including pre-clinical, clinical, regulatory and pharmaceutical sciences for PaxMedica's pipeli

      10/24/22 8:00:00 AM ET
      $PXMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $PXMD
    Financials

    Live finance-specific insights

    See more
    • PaxMedica Acquires Suramin Research Assets from Rediscovery Life Sciences to Accelerate NDA Submission for PAX-101

      TARRYTOWN, New York, Oct. 31, 2023 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (NASDAQ:PXMD), a pioneering biopharmaceutical company specializing in cutting-edge treatments for neurological disorders, announced today the successful acquisition of certain suramin research assets from Rediscovery Life Sciences (RLS). These assets were previously dedicated to the study of suramin's potential efficacy in treating acute kidney injury resulting from chronic kidney disease. The newly acquired data from RLS will play a crucial role in bolstering PaxMedica's ongoing efforts to support the submission for the approval of PAX-101, specifically for the treatment of African Sleeping Sickness cause

      10/31/23 8:00:00 AM ET
      $PXMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $PXMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by PaxMedica Inc.

      SC 13G/A - PaxMedica, Inc. (0001811623) (Subject)

      11/14/24 7:22:38 PM ET
      $PXMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by PaxMedica Inc. (Amendment)

      SC 13G/A - PaxMedica, Inc. (0001811623) (Subject)

      2/13/24 8:11:14 PM ET
      $PXMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by PaxMedica Inc.

      SC 13G - PaxMedica, Inc. (0001811623) (Subject)

      11/29/23 4:33:08 PM ET
      $PXMD
      Medicinal Chemicals and Botanical Products
      Health Care